Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2020-11-20 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Delårsrapport januari – september 2020' (Interim Report January – September 2020). It contains comprehensive financial data, including income statements, key performance indicators, and management commentary on business operations and clinical trial progress for the specified period. It is a formal quarterly/interim financial report, not an announcement of a report or a simple regulatory filing. 9M 2020
2020-11-20 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Report January – September 2020' and contains comprehensive financial data, including income statements, loss per share, and detailed management commentary on business operations, clinical trials, and strategic outlook. It covers a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2020
2020-11-20 English
Magnus Persson leaves the Board of Directors of Abliva AB to focus on role as founding partner at Eir Ventures
Board/Management Information Classification · 1% confidence The document explicitly announces that 'Magnus Persson leaves the Board of Directors of Abliva AB'. This content directly relates to a change in the company's board of directors or senior management. According to the definitions, this corresponds to the Board/Management Information category (MANG). The document is short and appears to be a press release announcing the change, not a comprehensive regulatory filing like a 10-K or IR. Therefore, MANG is the most appropriate classification.
2020-10-08 English
Magnus Persson lämnar styrelsen för Abliva AB för att fokusera på sin roll som grundare och partner i Eir Ventures
Board/Management Information Classification · 1% confidence The document announces that Magnus Persson is leaving the board of directors of Abliva AB to focus on his role at Eir Ventures. This is a direct announcement regarding a change in the company's board of directors or senior management. This aligns perfectly with the definition for Board/Management Information (MANG). The document is short and appears to be a press release or regulatory filing announcing this specific personnel change, not a comprehensive report like a 10-K or IR.
2020-10-08 Swedish
Abliva intends to start a pivotal KL1333 study second half 2021
Earnings Release Classification · 1% confidence The document is titled '# Press Release' and contains an announcement dated September 9, 2020, regarding a decision by the Board of Directors to accelerate a clinical program (KL1333) based on FDA feedback. It includes key highlights, management commentary, and concludes with a section titled 'Attachments' linking to a PDF document detailing the news. This structure—a brief announcement summarizing material news, often released via a regulatory wire service, rather than the full detailed report—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since the content is a specific, material business update (clinical trial acceleration and financing intent) rather than just a general regulatory filing, and it is presented as a 'Press Release' announcing news, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) if it's just a material event disclosure. Given the content is a specific, time-sensitive operational update (clinical trial acceleration and financing plans) announced via a 'Press Release' format, and it is not a full financial report (10-K, IR) or a transcript (CT), it is most appropriately classified as a general Regulatory Filing (RNS) as it serves as a broad disclosure mechanism for material, non-financial-period-specific news, or potentially an Earnings Release (ER) if this was the primary communication vehicle for operational updates. However, the text explicitly states: 'This information is information that Abliva AB is obliged to make public pursuant to the EU Market Abuse Regulation.' This strongly suggests a mandatory regulatory disclosure outside of standard periodic reports. Since it is not a specific financial report, the best fit among the options for a general, material regulatory announcement is RNS, although ER is plausible if this was part of an earnings cycle communication. Given the focus on clinical strategy and financing intent, RNS is the safest general classification for a press release disclosing material, non-financial-period-specific operational news. H2 2020
2020-09-09 English
Abliva avser att starta en pivotal klinisk studie med KL1333 under andra halvåret 2021
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces a significant update regarding the company's clinical trial plans for a drug candidate (KL1333), including interaction with the FDA and plans for financing. It explicitly states: "Denna information är sådan information som Abliva AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." (This information is information that Abliva AB is obliged to disclose pursuant to the EU's Market Abuse Regulation). This type of announcement, which communicates material, non-public information about operational and clinical progress, is typically classified as an Earnings Release (ER) if it were quarterly results, or a Regulatory Filing (RNS) if it's a general market announcement. Since it is a specific, material operational update that doesn't fit the strict definitions of ER (which is usually just financial highlights), 10-K, or IR, and it is a formal press release mandated by market rules, it falls best under the general Regulatory Filings category (RNS) or potentially an Earnings Release (ER) if the company uses press releases for all material updates. Given the content focuses heavily on clinical trial acceleration and FDA feedback, it is a material corporate event announcement. However, RNS is the designated fallback for general regulatory announcements not covered elsewhere. Since it is not a financial report itself (like 10-K or IR), nor a specific management/board change, nor a dividend notice, RNS is the most appropriate general classification for a mandatory market disclosure press release. Upon review, while it contains operational news, it is a formal press release mandated by market abuse regulation, making RNS the most suitable general regulatory disclosure category.
2020-09-09 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.